HUME PHBusiness Directories,Company Directories

Company Name: Corporate Name:	HUME PH
Company Title:
Company Description:
Keywords to Search:
Company Address:	2045 Av Carling,OTTAWA,ON,Canada
ZIP Code: Postal Code:	K2A
Telephone Number:	6137253991
Fax Number:
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	0
USA SIC Description:	FARM SUPLS AND FEED
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
HUMMER ADVENTURES
HUMMER CANADA
HUMMER ADVENTURES

Next company profile:
HUMANRESOLVE
HUMANITIES & SOCIAL SCIENCES
HUMANIST ASSOCIATION OF CANADA

Company News:

Endogenous Cushing’s Syndrome: Developing Drugs for Treatment
Drugs of different pharmacological classes are approved for the treatment of Cushing’s disease and or Cushing’s syndrome or for the treatment of symptoms (e g , hyperglycemia)
New Trends in Treating Cushing’s Disea - touchENDOCRINOLOGY
Rates disease after surgical treatment are high Recently, advances in molecular insights and a better understanding of pathophysiology have enabled the development of potential therapeutic targets that could control adrenocorticotropic hormone (ACTH) and cortisol secretio
Clinical management of patients with Cushing syndrome treated with . . .
Safe and effective use of mifepristone requires clinical judgment and close patient monitoring to ensure optimal clinical outcomes These consensus recommendations provide useful, practical guidance to clinicians using mifepristone
Frontiers | Effectiveness of Medical Treatment of Cushing’s Disease: A . . .
Objective: The objective of this systematic review was to evaluate the effectiveness and safety of pasireotide, cabergoline, ketoconazole, levoketoconazole, metyrapone, osilodrostat, and temozolomide for the treatment of Cushing’s disease (CD)
Medical Management of Cushing’s Syndrome: Current and . . . - Springer
We provide here a review of current and near-future medical options to treat Cushing’s syndrome, and discuss updates on clinical trials and the efficacy and safety of novel or in-development drugs, as well as future potential targets
Sparrow Pharmaceuticals Announces Completion of Phase 2 Trial and FDA . . .
The RESCUE trial was a randomized, placebo-controlled trial of clofutriben for ACTH-dependent endogenous Cushing’s syndrome, a rare disease caused by a tumor that leads to hypersecretion of cortisol
Experimental drug improves Cushing’s disease — Harvard Gazette
A new investigational drug significantly reduced urinary cortisol levels and improved symptoms of Cushing’s disease in the largest clinical study of this endocrine disorder ever conducted
University of California Health Cushings Syndrome Clinical Trials . . .
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome Do you qualify for these Cushing's Syndrome studies? We're researching treatments for 2025
Possible first-in-class Cushings disease treatment is being. . .
Lundbeck has launched a Phase 2 clinical trial to assess the efficacy, safety, and tolerability of Lu AG13909, a potential first-in-class treatment for Cushing’s disease
Cushing’s syndrome – Overview of Information and Clinical Research
The trial aims to provide a comprehensive understanding of the effects of SPI-62 on patients with Cushing’s Syndrome, focusing on both safety and efficacy The study’s findings will contribute to the development of new therapeutic strategies for managing this complex hormonal disorder